By Mill Chart
Last update: Jan 12, 2024
Consider AMGEN INC (NASDAQ:AMGN) as a top pick for dividend investors, identified by our stock screening tool. NASDAQ:AMGN shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NASDAQ:AMGN was assigned a score of 7 for dividend:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:AMGN has earned a 5 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:AMGN, the assigned 8 is a significant indicator of profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Our latest full fundamental report of AMGN contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
AMGEN INC
NASDAQ:AMGN (4/26/2024, 7:00:00 PM)
After market: 270.3 +0.32 (+0.12%)269.98
+0.6 (+0.22%)
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...
These two pharma stocks have followed distinct paths of late. Which is the better investment?
This Vanguard growth fund is home to some of the world's most innovative companies.
Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.
Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.